Last quarter (Q3 2023), Neumora Therapeutics, Inc.'s total revenue was £―, a decrease of ― from previous quarter. In Q3, Neumora Therapeutics, Inc.'s net income was £-53.03M. See Neumora Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 22
Total Revenue	-
Cost of Revenue	-
Gross Profit	-
Operating Expense	£ 135.87M
Operating Income	£ -135.87M
Net Non Operating Interest Income Expense	£ 4.56M
Other Income Expense	£ -405.00K
Pretax Income	£ -130.90M
Tax Provision	-
Earnings From Equity Interest Net Of Tax	-
Net Income Common Stockholders	£ -130.90M
Basic EPS	£ -4.81
Diluted EPS	£ -4.81
Basic Average Shares	£ 27.21M
Diluted Average Shares	£ 27.21M
Dividend Per Share	-
Total Operating Income As Reported	-
Reported Normalized Basic E P S	-
Reported Normalized Diluted E P S	-
Rent Expense Supplemental	-
Total Expenses	£ 135.87M
Net Income From Continuing And Discontinued Operation	£ -130.90M
Normalized Income	-
Interest Expense	-
EBIT	-
EBITDA	-

Currency in GBP

Neumora Therapeutics, Inc. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing